IRIDEX Corporation — FY2017 Form 10-K
Business and period: Iridex develops and sells ophthalmic laser systems, delivery devices and recurring-use probes and service products for glaucoma and retinal disease. Fiscal 2017 was the 52-week year ended December 30, 2017; the filing also reports fourth-quarter results. Its MicroPulse technology is a key part of its glaucoma and medical-retina strategy.
Financial performance and position
| Metric | FY2017 | FY2016 |
|---|---|---|
| Revenue | $41.6 million | $46.2 million |
| Gross profit / margin | $15.5 million / 37.3% | $20.8 million / 45.1% |
| Operating loss | $12.9 million | $2.6 million |
| Net loss | $12.9 million; $1.11 per diluted share | $11.7 million; $1.15 per diluted share |
| Cash from operations | $(3.6) million | $(0.1) million |
| Cash and cash equivalents at year-end | $21.7 million | $23.7 million |
| Working capital | $29.1 million | $37.7 million |
| Debt | No borrowings | No borrowings |
FY2017 revenue comprised $23.0 million in the United States, $8.1 million in Europe, $2.3 million in the rest of the Americas and $8.2 million in Asia/Pacific. International sales were 44.7% of revenue. The company reported a $15 million asset-based revolving credit facility, expiring November 2019, with no amount outstanding at year-end; availability is subject to a receivables borrowing base.
Fourth-quarter FY2017 revenue was $10.2 million, gross profit $2.2 million and net loss $5.2 million. For comparison, fourth-quarter FY2016 revenue was $12.5 million and net loss $10.8 million.
Changes versus prior period
- Revenue fell 10.0% from FY2016, with domestic and international system revenue down $2.3 million and $2.0 million, respectively; recurring revenue declined $0.3 million. Retina product sales were a principal factor.
- Gross margin contracted 7.8 percentage points. Management cited recall-related costs, less favorable product and geographic mix, lower retina selling prices and higher manufacturing variances.
- Operating expenses increased to $28.4 million from $23.4 million. Sales and marketing rose 41.4% to $14.5 million, principally due to increased headcount, commissions and trade-show spending.
- Operating cash use increased to $3.6 million. Cash declined by $2.0 million over the year; financing included $2.3 million net proceeds from a stock issuance.
- Loss from operations increased substantially, while the reported net loss was less than the operating loss in part because FY2017 included a $0.1 million income-tax benefit. FY2016 included a $9.1 million tax provision related largely to valuation allowances.
Outlook, risks and unusual items
- Outlook: No quantified revenue or earnings guidance is provided. Management said existing cash and cash equivalents should cover anticipated cash needs for the next 12 months. It expects international sales to remain significant and gross margins to fluctuate with sales mix, volume and manufacturing factors.
- Product recall: On February 23, 2018, the company initiated a voluntary recall of 104 TruFocus LIO Premiere accessories after reports of three adverse events. The company recorded in FY2017 an estimated $0.8 million revenue reduction from increased sales-return allowances and $1.3 million of additional cost of sales for inventory write-downs, replacements and related warranty costs.
- Litigation: In January 2018, Iridex sued Quantel entities, alleging patent and MicroPulse trademark infringement and breach of an earlier agreement. The outcome is uncertain.
- Operating and market risks: Risks include dependence on distributors and sole- or limited-source suppliers; manufacturing, quality and product reliability issues; competitive and pricing pressure; uncertain adoption and clinical evidence for new applications; reimbursement changes; and foreign-exchange effects on international competitiveness.
- Regulation and compliance: Medical-device clearances, ongoing FDA and quality-system compliance, continued European certification, and changing EU requirements may increase costs or delay product launches. The filing also discusses healthcare-law compliance exposure and states the company did not have a formal healthcare compliance program in place.
- Tax and commitments: A full valuation allowance was maintained against U.S. deferred tax assets; FY2017 year-end valuation allowance was $12.3 million. The Tax Cuts and Jobs Act was not expected to have a material FY2017 financial-statement impact. Contractual obligations included $5.7 million of operating-lease payments and $12.4 million of supplier and contract-manufacturer commitments.
- Audit and controls: The auditor issued unqualified opinions on the financial statements and internal control over financial reporting; management also concluded controls were effective.
Investor facts to verify
- Assess the recall’s final costs, remediation, customer response and any further adverse-event or regulatory disclosures.
- Track revenue recovery, particularly retina systems sales, G6-related probe adoption and revenue recognition under the Laser Advantage Program.
- Determine whether gross margin and operating costs improve after FY2017’s recall charges, unfavorable mix and expanded sales spending.
- Monitor operating cash burn, cash runway, supplier commitments and the actual availability and terms of the revolving credit facility.
- Follow the Quantel litigation and any implications for MicroPulse intellectual property, licensing or royalties.
- Evaluate evidence of clinical adoption and reimbursement support for MicroPulse procedures, alongside evolving FDA and EU requirements.